{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:53:08Z","timestamp":1780372388215,"version":"3.54.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jaad.2015.02.004","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T01:01:54Z","timestamp":1425517314000},"page":"917-919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis"],"prefix":"10.1016","volume":"72","author":[{"given":"Jashin J.","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Rowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith D.","family":"Bebchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2015.02.004_bib1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2015.02.004_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2796.2012.02593.x","article-title":"Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study","volume":"273","author":"Ahlehoff","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaad.2015.02.004_bib3","doi-asserted-by":"crossref","unstructured":"Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. doi:10.1111\/jdv.12768. Published online. October 10, 2014.","DOI":"10.1111\/jdv.12768"},{"key":"10.1016\/j.jaad.2015.02.004_bib4","first-page":"159","article-title":"No association between tumor necrosis factor inhibitor therapy and hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and\u00a0rheumatoid arthritis patients","volume":"14","author":"Wu","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2015.02.004_bib5","unstructured":"Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. Total cholesterol, HDLc, LDLc and triglycerides levels in TNF inhibitor-treated patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis. Int J Dermatol. In press."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215001231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215001231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:35:23Z","timestamp":1759271723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215001231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0190962215001231"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.02.004","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}